# SUPPORT FOR THE PRECLINICAL DEVELOPMENT OF EIF4A INHIBITORS ROCAGLAMIDE AND DIDESMETHYLROCAGLAMIDE. (TOXICIOLOGY SERVICES TO SUPPORT PRECLINICAL DRUG

> **NIH NIH N01** · IIT RESEARCH INSTITUTE · 2020 · $588,615

## Abstract

Support for the Preclinical Development of eIF4A inhibitors Rocaglamide and Didesmethylrocaglamide

## Key facts

- **NIH application ID:** 10281213
- **Project number:** 261201600015I-0-759102000001-1
- **Recipient organization:** IIT RESEARCH INSTITUTE
- **Principal Investigator:** DAVID MCCORMICK
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $588,615
- **Award type:** —
- **Project period:** 2020-09-23 → 2021-09-22

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10281213

## Citation

> US National Institutes of Health, RePORTER application 10281213, SUPPORT FOR THE PRECLINICAL DEVELOPMENT OF EIF4A INHIBITORS ROCAGLAMIDE AND DIDESMETHYLROCAGLAMIDE. (TOXICIOLOGY SERVICES TO SUPPORT PRECLINICAL DRUG (261201600015I-0-759102000001-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10281213. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*